Company Reports Q4 Revenue of $9.04M
Reports Q4 revenue $9.04M vs. $9.16M last year.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on UTMD
About UTMD
About the author
Utah Medical Products Reports Q4 Earnings
- Earnings Per Share: Utah Medical Products (UTMD) reported a GAAP EPS of $0.80 for Q4, indicating the company's ability to maintain profitability amidst market challenges.
- Revenue Performance: The revenue for Q4 stood at $9.04 million, reflecting a relatively stable income level despite a projected 5.8% decline in sales for 2025, showcasing the company's market adaptability.
- Gross Profit Analysis: The gross profit for Q4 2025 was $2,142, which is 8.9% lower than in 2024, yet the company successfully limited the dilution of its gross profit margin, demonstrating effective cost control.
- Sales Trends: Despite a 1.2% decline in sales for Q4, gross profit was only $59 (1.1%) lower than Q4 2024, indicating the company's ability to sustain relatively stable profitability even in the face of declining sales.
UTMD Reports Year-over-Year Decline in Q3 Earnings Due to Trade Disruptions and Margin Pressures
Stock Performance: Utah Medical Products, Inc. (UTMD) shares have declined 4.1% following a disappointing earnings report for Q3 2025, contrasting with a 2.8% growth in the S&P 500 during the same period.
Earnings and Revenue Decline: The company reported a 19.9% drop in earnings per share (EPS) to 82 cents and a 1.9% decrease in revenue to $9.8 million, attributed to trade disruptions and a weaker sales pipeline.
Operational Challenges: Significant factors impacting performance included unexpected order cancellations from non-U.S. distributors, increased manufacturing costs due to tariffs, and reduced sales from a former major customer, PendoTECH.
Future Outlook: Management revised full-year 2025 revenue expectations to a 7% decline, reflecting ongoing economic challenges, while also highlighting strong cash generation capabilities through share repurchases and dividends.
